Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...
GlobalData on MSN
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
The Jaypirca application moves to the EC for a decision, expected within the next one to two months.
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab ...
"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.
The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.
From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...
The FDA has approved oral acalabrutinib (Calquence, AstraZeneca) in combination with venetoclax (Venclexta, AbbVie and Genentech) for the first-line treatment of adults with chronic lymphocytic ...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending a new oral treatment for people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results